David Setboun, Pharm.D., MBA

PharmatrophiX is a clinical‑stage neurodegeneration company developing first‑in‑class small‑molecule modulators of the p75 neurotrophin receptor to build brain resilience. Its lead program targets Alzheimer’s disease and rare neurodegenerative disorders such as PSP and Huntington’s disease. PharmatrophiX is focused on translating differentiated science into value‑creating clinical milestones and long‑term therapeutic impact for patients and investors.

Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease. Additional information can be found on the company’s website at www.alkeus.com.

The Academy the world’s first global non-profit comprised of some of the best and brightest aging scientists united to accelerate breakthroughs in longevity. Our Vision We envision a world where breakthroughs in longevity are accelerated and made accessible because the most brilliant researchers, laboratories, academic institutions, regulators and drug companies are collaborating in new and innovative ways. Our Mission Our mission is accelerate the development of scientific documented interventions that will promote longer, healthier, more productive and more rewarding lives for all members of humanity. These interventions could potentially include life style alterations, nutritional modifications, pharmaceuticals, medical practice innovations and environmental improvements.

DISCOVER. INNOVATE. DELIVER. Delivering on the Promise of Cellular Therapeutics. BrainStorm is focused on developing clinical-stage autologous cellular therapy as a potentially transformative approach to treating neurodegenerative diseases through a targeted, innovative, proprietary and validated autologous cellular technology platform (NurOwn®) for the treatment of neurodegenerative diseases.

Accountable for the vision, strategy and execution of Biogen strategy for the french affiliate. Passion for Rare disease, building from scratch Spinraza team, ensuring strong access evaluation, early uptake of access programs. Creating first meetings with KOLs and building patient association interactions. Create relationship with main CRO to ensure strong execution of phase I to phase IV studies within the affiliate. Maintain Multiple Sclerosis business despite price decreases, launching successfully Plegridy and turn around of Tysabri. Start building Alzheimer medical presence and government interactions. Ensure Biosimilar franchise development and acceleration in France.

Selected to direct vision, strategy, and execution for product management, revenue and breaking new ground with the launch of three brands in a country under Troika management with new access to medicine blocked since 2011 Achieved a demonstrated record of strong financial performance, surpassing SM&M ratio target in 2012 and above revenue targets for 2013, having positioned the company as the only firm driving access to new and innovative products in the current year. Bring company to growth in 2015 and from 6th national ranking in 2012 to 3rd national ranking in 2015. Launched successfully 5 new brands Spearheaded a major reorganization of personnel, driving a strong headcount reduction in 2012 without compromising the effectiveness of operations Assumed a lead role shaping industry association agenda as a Board Member Motivates Astrazeneca personnel and achieved a leading ranking as best place to work in Portugal

Directed the efforts of a team of 20 executives engaged in marketing, market access, and commercial strategy, developing innovative and effective sales and marketing tactics designed to increase European market share and drive revenue; achieved and maintained exceedingly high leadership and engagement scores Outperformed all revenue targets, and sparking business model transformation by actively creating and developing new sales and revenue channels; developed multiple business development analysis, company presentations, and deals to drive and support the creation and cultivation of new client relationships Partnered with McKinsey to drive innovations in EU Strategy, Payers & commercial transformation, shaping the structure of new EU marketing companies Accelerated launch plans for CV hospital brand and Oncology across Europe markets

Entrusted with the effective management of Cymbalta based in the US team with International launch for neuropathic pain , engaging in brand planning strategy, business plan development Successfully launched the Cymbalta brand. Gathered input from global medical teams on Phase III studies, Phase II development progress, and price and access strategies